ArticleJournal of the American Heart Association2026
Paclitaxel Efficacy in Dialysis-Dependent Peripheral Artery Disease: A National Cohort Analysis.
Article in Journal of the American Heart Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients undergoing dialysis have a significant risk of peripheral artery disease, limb amputation, and mortality. Paclitaxel-coated devices (PCDs) are used to reduce restenosis after endovascular therapy, but their safety and efficacy in a dialysis-dependent population remain unclear. We aimed to evaluate the association between PCDs and major clinical outcomes in patients with maintenance dialysis undergoing endovascular therapy for symptomatic peripheral artery disease.
methodsWe conducted a nationwide retrospective cohort analysis using the National Health Insurance Research Database in Taiwan. Patients under dialysis receiving endovascular therapy between May 2016 and December 2022 were included. Patients were categorized into PCD and non-PCD groups during the index procedure. Propensity score matching was performed to balance baseline characteristics. The primary outcome was defined as the composite of lower limb amputation or all-cause mortality. Cardiovascular outcomes and clinical-driven reintervention were secondary outcomes.
resultsAmong 10 235 eligible patients, 1169 (11.4%) received PCDs. After 1:3 matching, 1160 and 3480 patients in the PCD and non-PCD groups were analyzed. PCD use was associated with a significantly lower risk of the primary outcome (47.6% versus 52.2%; hazard ratio [HR], 0.85 [95% CI, 0.77-0.93]). Risks of amputation (20.7% versus 23.8%; subdistribution HR, 0.84 [95% CI, 0.73-0.97]) and all-cause mortality (35.9% versus 38.9%; HR, 0.87 [95% CI, 0.78-0.97]) were also significantly lower with PCD use. Cardiovascular outcomes and clinical-driven reintervention were similar between groups.
conclusionsUse of PCD in dialysis-dependent patients undergoing endovascular therapy for peripheral artery disease was associated with reduced risk of the composite outcome of amputation and all-cause mortality.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.